These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 27792701

  • 1. [Long-term destiny of adolescents and young adults with de novo acute lymphoblastic leukemia treated with a pediatric protocol type].
    López-Hernández MA, Alvarado-Ibarra M, Álvarez-Veral JL, Ortiz-Zepeda M, Guajardo-Leal ML, Cota-Range X.
    Gac Med Mex; 2016; 152(5):439-443. PubMed ID: 27792701
    [Abstract] [Full Text] [Related]

  • 2. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
    Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM.
    Cancer; 2014 Dec 01; 120(23):3660-8. PubMed ID: 25042398
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
    Ribera JM, Oriol A, Sanz MA, Tormo M, Fernández-Abellán P, del Potro E, Abella E, Bueno J, Parody R, Bastida P, Grande C, Heras I, Bethencourt C, Feliu E, Ortega JJ.
    J Clin Oncol; 2008 Apr 10; 26(11):1843-9. PubMed ID: 18398150
    [Abstract] [Full Text] [Related]

  • 4. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
    Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR.
    Blood; 1995 Apr 15; 85(8):2025-37. PubMed ID: 7718875
    [Abstract] [Full Text] [Related]

  • 5. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM, Ribera JM, Xicoy B, Morgades M, Oriol A, Tormo M, del Potro E, Debén G, Abella E, Bethencourt C, Ortín X, Brunet S, Ortega-Rivas F, Novo A, López R, Hernández-Rivas JM, Sanz MA, Feliu E, PETHEMA Group.
    Eur J Haematol; 2007 Feb 15; 78(2):102-10. PubMed ID: 17087744
    [Abstract] [Full Text] [Related]

  • 6. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, Moorman AV, Wade R.
    Lancet Oncol; 2014 Jul 15; 15(8):809-18. PubMed ID: 24924991
    [Abstract] [Full Text] [Related]

  • 7. Long-term Results of the Risk-adapted Treatment for Childhood B-Cell Acute Lymphoblastic Leukemia: Report From the Japan Association of Childhood Leukemia Study ALL-97 Trial.
    Horibe K, Yumura-Yagi K, Kudoh T, Nishimura S, Oda M, Yoshida M, Komada Y, Hara J, Tawa A, Usami I, Tanizawa A, Kato K, Kobayashi R, Matsuo K, Hori H, Japan Association of Childhood Leukemia Study (JACLS), Japan.
    J Pediatr Hematol Oncol; 2017 Mar 15; 39(2):81-89. PubMed ID: 28169879
    [Abstract] [Full Text] [Related]

  • 8. Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect.
    Chiu EK, Chan LC, Liang R, Lie A, Kwong YL, Todd D, Chan TK.
    Leukemia; 1994 Sep 15; 8(9):1469-73. PubMed ID: 8090027
    [Abstract] [Full Text] [Related]

  • 9. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
    Testi AM, Canichella M, Vitale A, Piciocchi A, Guarini A, Starza ID, Cavalli M, De Propris MS, Messina M, Elia L, Moleti ML, Martino B, Luppi M, D'Aloisio M, Candoni A, Conter V, Fazi P, Vignetti M, Chiaretti S, Foà R.
    Am J Hematol; 2021 Mar 01; 96(3):292-301. PubMed ID: 33284999
    [Abstract] [Full Text] [Related]

  • 10. Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
    Pedrosa F, Coustan-Smith E, Zhou Y, Cheng C, Pedrosa A, Lins MM, Pedrosa M, Lucena-Silva N, Ramos AML, Vinhas E, Rivera GK, Campana D, Ribeiro RC.
    Blood; 2020 Apr 23; 135(17):1458-1466. PubMed ID: 32027741
    [Abstract] [Full Text] [Related]

  • 11. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia.
    Linker C, Damon L, Ries C, Navarro W.
    J Clin Oncol; 2002 May 15; 20(10):2464-71. PubMed ID: 12011123
    [Abstract] [Full Text] [Related]

  • 12. Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
    Hinze L, Möricke A, Zimmermann M, Junk S, Cario G, Dagdan E, Kratz CP, Conter V, Schrappe M, Stanulla M.
    Leukemia; 2017 Aug 15; 31(8):1840-1842. PubMed ID: 28529312
    [No Abstract] [Full Text] [Related]

  • 13. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study.
    Sandlund JT, Pui CH, Zhou Y, Behm FG, Onciu M, Razzouk BI, Hijiya N, Campana D, Hudson MM, Ribeiro RC.
    Leukemia; 2009 Jun 15; 23(6):1127-30. PubMed ID: 19194463
    [Abstract] [Full Text] [Related]

  • 14. A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia.
    Kim SY, Park JH, Yoon SY, Cho YH, Lee MH.
    Cancer Chemother Pharmacol; 2018 Feb 15; 81(2):393-398. PubMed ID: 29294168
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A, Lutz P, Mechinaud F, Robert A, Boutard P, Marguerite G, Ferster A, Plouvier E, Rialland X, Behard C, Plantaz D, Dresse MF, Philippet P, Norton L, Thyss A, Dastugue N, Waterkeyn C, Vilmer E, Otten J, Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer.
    J Clin Oncol; 2001 Apr 01; 19(7):1935-42. PubMed ID: 11283125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.